Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

930601

Sigma-Aldrich

VH032-cyclopropane-F

≥95%

Sinónimos:

(S,R,S)-AHPC-cyclopropane-F, (2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, (2S,4R)-1-[(S)-2-(1-Fluorocyclopropan-1-ylcarbonylamino)-3,3-dimethylbutanoyl]-4-hydroxy-N-[2-hydroxy-4-(4-methylthiazol-5-yl)benzyl]pyrrolidine-2-carboxamide, N-[(1-fluorocyclopropyl)carbonyl]-3-methyl-L-valyl-4-hydroxy-N-[[2-hydroxy-4-(4-methyl-5-thiazolyl)phenyl]methyl]-, (4R)-, L-Prolinamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C26H33FN4O5S
Número de CAS:
2306193-99-5
Peso molecular:
532.63
Número MDL:
MFCD32201089
Código UNSPSC:
12352101
NACRES:
NA.22

ligand

VH032

Nivel de calidad

100

Ensayo

≥95%

Formulario

powder

idoneidad de la reacción

reagent type: ligand

grupo funcional

hydroxyl

temp. de almacenamiento

2-8°C

cadena SMILES

C([C@@H](NC(=O)C1(F)CC1)[C@@](C)(C)C)(=O)N2[C@H](C(NCC3=C(O)C=C(C=C3)C4=C(C)N=CS4)=O)C[C@@H](O)C2

Clave InChI

OKBLHQUBMCCFKE-LVCYWYKZSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Aplicación

VH032-cyclopropane-F is a functionalized von-Hippel-Lindau (VHL) ligand with a terminal hydroxyl group. Allows rapid conjugation with many linkers containing active leaving groups. A basic building block for development of a protein degrader library.

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks

Otras notas

Targeted Protein Degradation by Small Molecules


Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O′PROTAC): Effective Targeting of LEF1 and ERG3


Small-Molecule PROTACS: New Approaches to Protein Degradation


Targeted Protein Degradation: from Chemical Biology to Drug Discovery


Impact of linker length on the activity of PROTACs

Información legal

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000204819

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Jingwei Shao et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(20), e2102555-e2102555 (2021-08-17)
DNA-binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand-binding
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico